As add-on maintenance treatment for patients (12+ years) with moderate-to-severe asthma with an eosinophilic phenotype, or with OCS-dependent asthma regardless of phenotype. Limitation of Use: DUPIXENT is not indicated for the relief of acute bronchospasm or status asthmaticus.
This site is intended for U.S. Healthcare Professionals only.
Do you wish to continue?
You are leaving a Sanofi US website
Are you sure you want to leave?
Please note: By clicking on this link, you will be leaving this Sanofi hosted US website and going to another, entirely independent, website. Sanofi US and Regeneron provide these links as a service to its website visitors and users; however, they take no responsibility for the information on any website but its own.
You are about to leave sanofi site for U.S.
Sanofi US does not review the information
contained on this website and/or database
for content, accuracy or completeness. Use
of and access to this information is subject to
the terms, limitations and conditions set by the
website and/or database producer.
This site might not comply with the regulatory requirements of US